These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20637102)

  • 1. FDG-PET staging and importance of lymph node SUV in head and neck cancer.
    Kubicek GJ; Champ C; Fogh S; Wang F; Reddy E; Intenzo C; Dusing RW; Machtay M
    Head Neck Oncol; 2010 Jul; 2():19. PubMed ID: 20637102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer.
    Fogh SE; Kubicek GJ; Champ C; Intenzo C; Axelrod R; Keane WM; Machtay MM
    Am J Clin Oncol; 2012 Aug; 35(4):311-5. PubMed ID: 22772424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.
    Schinagl DA; Span PN; Oyen WJ; Kaanders JH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1449-58. PubMed ID: 21461734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose uptake level-based lymph node staging in oropharyngeal squamous cell cancer--role of molecular marker expression on diagnostic outcome.
    Sadick M; Weiss C; Piniol R; Frey S; Hoermann K; Schoenberg SO; Sadick H
    Oncol Res Treat; 2015; 38(1-2):16-22. PubMed ID: 25633529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
    World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer.
    Yamazaki Y; Saitoh M; Notani K; Tei K; Totsuka Y; Takinami S; Kanegae K; Inubushi M; Tamaki N; Kitagawa Y
    Ann Nucl Med; 2008 Apr; 22(3):177-84. PubMed ID: 18498032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?
    Schinagl DA; Hoffmann AL; Vogel WV; van Dalen JA; Verstappen SM; Oyen WJ; Kaanders JH
    Radiother Oncol; 2009 Apr; 91(1):95-100. PubMed ID: 19285354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy.
    Seol YM; Kwon BR; Song MK; Choi YJ; Shin HJ; Chung JS; Cho GJ; Lee JC; Lee BJ; Wang SG; Kim HJ; Kim WT; Kim SJ; Yun EY
    Acta Oncol; 2010; 49(2):201-8. PubMed ID: 20100156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis.
    Schmidt M; Schmalenbach M; Jungehülsing M; Theissen P; Dietlein M; Schröder U; Eschner W; Stennert E; Schicha H
    Nuklearmedizin; 2004 Jun; 43(3):91-101;quiz 102-4. PubMed ID: 15201950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.
    Chu KP; Murphy JD; La TH; Krakow TE; Iagaru A; Graves EE; Hsu A; Maxim PG; Loo B; Chang DT; Le QT
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1521-7. PubMed ID: 22270168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer.
    Tan R; Yao SZ; Huang ZQ; Li J; Li X; Tan HH; Liu QW
    Asian Pac J Cancer Prev; 2014; 15(18):7719-24. PubMed ID: 25292052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.